Navigation Links
Hard to Treat Diseases, Inc. (HTDS) Reports on New Uses For Ribavirin
Date:5/20/2009

BELGRADE, SERBIA, May 20 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK)http://www.htdsmedical.com reports that researchers in its Slavica BioChem division have advised of some significant new advances recently announced regarding the drug Ribavirin; one of the drugs with which they are currently conducting research.

On Wednesday, May 13, 2009, Health and Medicine Magazine reported that:

        A ground-breaking Canada-wide clinical trial led by Dr. Katherine
        Borden, at the Institute for Research in Immunology and Cancer (IRIC)
        of the Universite de Montreal, has shown that a common anti-viral
        drug, ribavirin, can be beneficial in the treatment of cancer
        patients. Published in the journal Blood (First Edition), the study
        demonstrates that ribavirin suppresses the activities of the eIF4E
        gene in patients. This gene is dysregulated in 30 percent of cancers
        including breast, prostate, head and neck, colon and stomach cancer.

Interested readers can view a CTV news report on the story at http://watch.ctv.ca/news/top-picks/old-drug-new-use/#clip173867 .

The story is of interest as Slavica BioChem is currently conducting research into the use of Ribavirin for use in the treatment of diseases of the Central Nervous system such as Multiple Sclerosis (MS). Studies conducted involved using a combination of ribavirin and tiazofurin and have shown promising results in test animals to date.

One of the benefits of working with established drugs such as ribavirin, which has been in use approximately twenty years, is that the significant experience and history of the drug make it easier to obtain approval for use in new applications, such as the research that has been conducted by Slavica BioChem.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc. 's control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. Note this CTV web link is an unauthorized link, provided for the convenience of the reader.

CONTACT: corporate@HTDScorporation.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Using coxibs and NSAIDs to treat osteoarthritis
2. New treatment effective in counteracting cocaine-induced symptoms
3. New treatment boosts muscle function in myasthenia gravis
4. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
5. Free distribution of insecticide-treated mosquito nets can save lives
6. Kenyan malaria success strengthens call for free insecticide-treated nets for all
7. Broad-based group of physicians calls for improvement in stroke treatment
8. Cranberry Could Juice Up Ovarian Cancer Treatment
9. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
10. Non-medicinal treatment touted for pre-schoolers with ADHD
11. Nonmedicinal treatment touted for preschoolers with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... ... Neil H. Greco Insurance Agency, a northern New Jersey firm that provides ... a charity drive to raise awareness of heart disease and promote habits that improve ... is responsible for 1 in every 4 deaths at the national level each year. ...
(Date:1/17/2017)... , ... January 17, 2017 , ... SC&H Group, a ... as a Principal in its IT Advisory Services practice . Rossi is the ... as market demand for strategic IT guidance grows, and the practice continues to expand.     ...
(Date:1/17/2017)... Westford, Mass. (PRWEB) , ... January 17, 2017 ... ... management company to visualize, detect, and eliminate cyber threats in real-time, today announced ... and Solutions provider, headquartered in Selangor, Malaysia. Joining other Seceon partners, TechLab Security ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... offices in Tyler, has announced the latest beneficiary of their thriving community involvement ... nonprofit organization dedicated to fulfilling the dreams of terminally ill patients. Donations to ...
(Date:1/17/2017)... ... January 17, 2017 , ... Many people make New Year’s resolutions or renew their ... is making it easier for people who want to kick off 2017 with better ... existing patients. , These special offers include: , , A ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017 Interpace Diagnostics Group, ... clinically useful molecular diagnostic tests and pathology services for ... received a letter dated January 13, 2017 from the ... regained compliance with the requirement of the NASDAQ Stock ... $1.00 per share. The letter noted that ...
(Date:1/17/2017)... Research and Markets has announced the addition of the "The Top ... ... and profiles the leading 200 manufacturers and distributors of molecular diagnostics products ... United States and Europe to ... Profile information for each company in The Top 200 Molecular Diagnostics ...
(Date:1/17/2017)... LONDON , January 17, 2017 ... Review, 2016;11(Suppl. 1):2-4 ; http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ... ... Published recently in European ... from touchNEUROLOGY, Catherine Amey reports that ...
Breaking Medicine Technology: